What's New

News

2019/10/01
MicroChem Corp (MCC) has changed its name to Kayaku Advanced Materials, Inc.(KAM)
2019/09/30
Updated information of CSR
2019/08/21
Trastuzumab BS for I.V. Infusion 60mg “NK”・150mg “NK” Obtained Approval for Additional Dosage & Administration of Breast Cancer with HER2 Overexpression
2019/06/18
Transfer of Marketing Authorization for humanized anti EGFR Monoclonal Antibody PORTRAZZA, in JAPAN
2019/05/30
Management Changes (Appointments & Transfers)
2019/04/22
NIPPON KAYAKU and Eli Lilly Enter into Licensing Agreement of Necitumumab, a humanized anti EGFR Monoclonal Antibody, in JAPAN
PageTop
Corporate Vision
Our Business
Corporate Information
Global Netowork
Investor Relations
CSR